Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa
Journal of the International AIDS Society, Volume 15, No. 1, Article 2, Year 2012
Notification
URL copied to clipboard!
Description
Background: The introduction of C-C chemokine receptor type-5 (CCR5) antagonists as antiretroviral therapy has led to the need to study HIV co-receptor tropism in different HIV-1 subtypes and geographical locations. This study was undertaken to evaluate HIV-1 co-receptor tropism in the developing world where non-B subtypes predominate, in order to assess the therapeutic and prophylactic potential of CCR5 antagonists in these regions. Methods. HIV-1-infected patients were recruited into this prospective, cross-sectional, epidemiologic study from HIV clinics in South Africa, Uganda and India. Patients were infected with subtypes C (South Africa, India) or A or D (Uganda). HIV-1 subtype and co-receptor tropism were determined and analyzed with disease characteristics, including viral load and CD4 + and CD8 + T cell counts. Results: CCR5-tropic (R5) HIV-1 was detected in 96% of treatment-nave (TN) and treatment-experienced (TE) patients in India, 71% of TE South African patients, and 86% (subtype A/A1) and 71% (subtype D) of TN and TE Ugandan patients. Dual/mixed-tropic HIV-1 was found in 4% of Indian, 25% of South African and 13% (subtype A/A1) and 29% (subtype D) of Ugandan patients. Prior antiretroviral treatment was associated with decreased R5 tropism; however, this decrease was less in subtype C from India (TE: 94%, TN: 97%) than in subtypes A (TE: 59%; TN: 91%) and D (TE: 30%; TN: 79%). R5 virus infection in all three subtypes correlated with higher CD4 + count. Conclusions: R5 HIV-1 was predominant in TN individuals with HIV-1 subtypes C, A, and D and TE individuals with subtypes C and A. Higher CD4 + count correlated with R5 prevalence, while treatment experience was associated with increased non-R5 infection in all subtypes. © 2012 Ataher et al; licensee BioMed Central Ltd.
Authors & Co-Authors
Ataher, Quazi
United States, New York
Pfizer Inc.
Portsmouth, Simon D.
United States, New York
Pfizer Inc.
Napolitano, Laura A.
United States, San Francisco
Monogram Biosciences
Eng, Sybil
United States, New York
Pfizer Inc.
Greenacre, Anna
United States, New York
Pfizer Inc.
Kambugu, Andrew Ddungu
Uganda, Kampala
Makerere University College of Health Sciences
Wood, Robin Y.
South Africa, Cape Town
University of Cape Town
Badal-Faesen, Sharlaa
South Africa, Johannesburg
Helen Joseph Hospital
Tressler, Randall L.
United States, New York
Pfizer Inc.
Statistics
Citations: 9
Authors: 9
Affiliations: 5
Identifiers
Doi:
10.1186/1758-2652-15-2
e-ISSN:
17582652
Research Areas
Infectious Diseases
Study Design
Cross Sectional Study
Cohort Study
Study Locations
South Africa
Uganda